Publications
154
Citations
3,943
Est. group size
~1
Recurring co-author estimate
Active years
37
Publishing since 1990
William C. Kisseberth studies cancer in dogs (veterinary oncology), with particular focus on bone cancer (osteosarcoma) and lymphoma, including their genetics, treatment approaches, and vaccine-based immunotherapies. This work often uses dogs as natural disease models that can also inform understanding of similar cancers in humans. Prospective students would be exposed to translational research combining clinical trials, molecular genetics, and cancer treatment development.
Publication output has fluctuated over the past decade, with a large spike in 2023 (driven largely by supplementary materials tied to a single osteosarcoma genetics study) followed by a decline in 2024-2026.
Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026
- Soft Tissue Sarcoma
2026
- Lymphoma
2026
- Immunological responses and clinical outcomes in dogs with osteosarcoma receiving standard therapy and a Listeria vaccine expressing HER2
Molecular Therapy · 2025
- Diagnosis and Classification of Primary Nodal Lymphomas in Dogs: A Consensus of the Oncology‐Pathology Working Group
Veterinary and Comparative Oncology · 2025
- Additional methods for putative drive genes discovery and oaCGH results from <i>SETD2</i> Is Recurrently Mutated in Whole-Exome Sequenced Canine Osteosarcoma
2023
- Additional methods for putative drive genes discovery and oaCGH results from <i>SETD2</i> Is Recurrently Mutated in Whole-Exome Sequenced Canine Osteosarcoma
2023
- Supplementary Figures 1-8 from <i>SETD2</i> Is Recurrently Mutated in Whole-Exome Sequenced Canine Osteosarcoma
2023
- Data from <i>SETD2</i> Is Recurrently Mutated in Whole-Exome Sequenced Canine Osteosarcoma
2023
- Supplementary Tables 1-14 from <i>SETD2</i> Is Recurrently Mutated in Whole-Exome Sequenced Canine Osteosarcoma
2023
- Supplementary Table 5 from <i>SETD2</i> Is Recurrently Mutated in Whole-Exome Sequenced Canine Osteosarcoma
2023
- Supplementary Table 4 from <i>SETD2</i> Is Recurrently Mutated in Whole-Exome Sequenced Canine Osteosarcoma
2023
- Supplementary Table 5 from <i>SETD2</i> Is Recurrently Mutated in Whole-Exome Sequenced Canine Osteosarcoma
2023
- Supplementary Table 14 from <i>SETD2</i> Is Recurrently Mutated in Whole-Exome Sequenced Canine Osteosarcoma
2023
- Supplementary Figures 1-8 from <i>SETD2</i> Is Recurrently Mutated in Whole-Exome Sequenced Canine Osteosarcoma
2023
- Data from <i>SETD2</i> Is Recurrently Mutated in Whole-Exome Sequenced Canine Osteosarcoma
2023
- Cancer Research×6
- Veterinary and Comparative Oncology×5
- PLoS ONE×4
- Clinical Cancer Research×3
- Frontiers in Veterinary Science×3
- Nikolaos Dervisis
Medicine · Purdue University West Lafayette
- Michael O. Childress
Medicine · Purdue University West Lafayette
- R. Timothy Bentley
Medicine · Purdue University West Lafayette
- Joelle M. Fenger
Medicine · The Ohio State University
- Maxey L. Wellman
Medicine · The Ohio State University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 19, 2026.
Claim or correct this profile